GFS Advisors LLC Cuts Stock Position in Johnson & Johnson $JNJ

GFS Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,767 shares of the company’s stock after selling 3,729 shares during the period. Johnson & Johnson comprises 1.2% of GFS Advisors LLC’s holdings, making the stock its 24th largest position. GFS Advisors LLC’s holdings in Johnson & Johnson were worth $10,299,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Paragon Private Wealth Management LLC raised its stake in shares of Johnson & Johnson by 5.8% in the fourth quarter. Paragon Private Wealth Management LLC now owns 7,378 shares of the company’s stock valued at $1,527,000 after buying an additional 404 shares during the period. Red Cedar Investment Management LLC raised its stake in shares of Johnson & Johnson by 211.2% in the fourth quarter. Red Cedar Investment Management LLC now owns 16,462 shares of the company’s stock valued at $3,407,000 after buying an additional 11,172 shares during the period. First Dallas Securities Inc. raised its stake in shares of Johnson & Johnson by 4.6% in the fourth quarter. First Dallas Securities Inc. now owns 11,497 shares of the company’s stock valued at $2,379,000 after buying an additional 501 shares during the period. GW&K Investment Management LLC raised its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. GW&K Investment Management LLC now owns 3,930 shares of the company’s stock valued at $813,000 after buying an additional 95 shares during the period. Finally, Outlook Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Outlook Wealth Advisors LLC now owns 12,821 shares of the company’s stock valued at $2,653,000 after buying an additional 307 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on JNJ. Stifel Nicolaus boosted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a research note on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a research note on Wednesday, May 13th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $236.88 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The firm has a market cap of $570.22 billion, a price-to-earnings ratio of 27.39, a PEG ratio of 2.27 and a beta of 0.26. The business’s fifty day moving average is $231.76 and its 200 day moving average is $226.61.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period in the previous year, the company posted $2.77 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a $1.34 dividend. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J’s $1 billion acquisition of Firefly Bio strengthens its oncology pipeline with Firelink DAC technology aimed at hard-to-treat KRAS-driven cancers, which could improve long-term growth prospects. Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story
• Positive Sentiment: NICE preliminarily recommended D-VRd for first-line treatment of transplant-ineligible multiple myeloma in the NHS, a potential commercial boost for J&J’s Darzalex franchise. J&J secures extended NICE approval for Darzalex following earlier refusal
• Positive Sentiment: Commentary around J&J’s strong oncology and MedTech execution, including recent product momentum, is helping fuel bullish sentiment and expectations for continued growth. Will Johnson & Johnson Stock Hit $300 This Year?
• Neutral Sentiment: J&J also presented at Goldman Sachs’ healthcare conference, but the transcript does not provide a clear new catalyst on its own. Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Broader sector articles highlighting healthcare as a defensive trade may provide background support, but they are not J&J-specific catalysts. Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
• Negative Sentiment: Some coverage noted patent and legal headwinds facing J&J, which remain a risk factor even as the company’s diversified business and pipeline help offset concerns. JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.